Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy Monitoring

The discussion was on Tuesday, December 7, 2021

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy Monitoring
 
Speakers –

Adam Brufsky, MD, PhD
Speaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case Studies

Giampaolo Bianchini, MD
Speaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive Biomarkers

Hope Rugo, MD
Speaks about Callenges and Opportunities for Optimizing Immunotherapies for TNBC